Publikationen in Zusammenarbeit mit Forschern von Radboud University Nijmegen Medical Centre (18)

2024

  1. Planetary Health: What You Need to Know as a Pediatric Infectious Diseases Doctor

    Pediatric Infectious Disease Journal

  2. Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial

    Clinical Infectious Diseases, Vol. 78, Núm. 3, pp. 702-710

2023

  1. Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change

    Journal of Acquired Immune Deficiency Syndromes, Vol. 93, Núm. 1, pp. 42-46

  2. First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia

    Journal of the Pediatric Infectious Diseases Society, Vol. 12, Núm. 11, pp. 581-585

  3. Genomic investigations of unexplained acute hepatitis in children

    Nature, Vol. 617, Núm. 7961, pp. 564-573

2022

  1. Advancing the prevention and treatment of HIV in children: priorities for research and development

    The lancet. HIV, Vol. 9, Núm. 9, pp. e658-e666

  2. Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 5, pp. e341-e352

  3. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 9, pp. e627-e637

  4. Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trial

    Trials, Vol. 23, Núm. 1

  5. What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies

    The Lancet HIV, Vol. 9, Núm. 9, pp. e649-e657

2021

  1. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

    New England Journal of Medicine, Vol. 385, Núm. 27, pp. 2531-2543

  2. Interferon-Gamma Release Assays Differentiate between Mycobacterium avium Complex and Tuberculous Lymphadenitis in Children

    Journal of Pediatrics, Vol. 236, pp. 211-218.e2

  3. Malignancies among children and young people with HIV in Western and Eastern Europe and Thailand the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) study group

    AIDS, Vol. 35, Núm. 12, pp. 1973-1985

2020

  1. Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: A systematic review

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3433-3457

  2. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

    The Lancet HIV, Vol. 7, Núm. 8, pp. e533-e544

2019

  1. Identification of regulatory variants associated with genetic susceptibility to meningococcal disease

    Scientific Reports, Vol. 9, Núm. 1

  2. Plasma lipid profiles discriminate bacterial from viral infection in febrile children

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life

    HIV Medicine, Vol. 19, Núm. 1, pp. e1-e42